Curriculum
Vitae
Research
Interest
My
current area of interest focuses on the metabolic bases for the
the early events in atherosclerosis, in particular, the role of
high density lipoproteins (HDL) in the development of the fatty
streak. Using a genetic approach, as well as molecular and
biochemical techniques, we investigate the dynamics between
lipoproteins and cells of the artery wall in the disease process.
Repesentative
Publications
Van Lenten BJ, Wagner AC, Jung CL,
Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M,
Anantharamaiah GM, and Fogelman AM. Anti-Inflammatory ApoA-I
Mimetic Peptides Bind Oxidized Lipids With Much Higher Affinity
Than Human ApoA-I. J Lipid Res (at press).
Navab M, Anantharamaiah GM, Reddy ST,
Van Lenten BJ and Fogelman AM. Apo A-1 Mimetic Peptides as
Atheroprotective Agents in Murine Models. Current Drug Targets, 9:
2008.
Navab M, Anantharamaiah GM, Reddy ST,
Van Lenten BJ and Fogelman AM Hyperlipidemia and Cardiovascular
Diseases. Curr Opin Lipidol 2008.
Van Lenten BJ, Alan C. Wagner,
Mohamad Navab, G. M. Anantharamaiah, Susan Hama, Srinivasa T. Reddy,
and Alan M. Fogelman. Lipoprotein Inflammatory Properties and Serum
Amyloid A Levels But Not Cholesterol Levels Predict Lesion Area in
Cholesterol-fed Rabbits. J Lipid Res 48:2344-2353, 2007.
Navab M, Yu R, Gharavi N, Huang W,
Ezra N, Lotfizadeh A, Anantharamaiah G M, Alipour N, Van Lenten BJ,
Reddy ST, Marelli D. High-density lipoprotein: Antioxidant and
anti-inflammatory properties. Curr Atheroscler Reports, 9(3):
244-248, 2007.
Van Lenten BJ, Reddy ST, Navab M, and
Fogelman AM. Understanding Changes in High Density Lipoproteins
During the Acute Phase Response. Arterioscler Thromb Vasc Biol 26:
1687-1688, 2006.
Navab M, Anantharamaiah GM, Reddy ST,
Van Lenten BJ, Datta G, Garber D, and Fogelman AM. Potential
clinical utility of high-density lipoprotein-mimetic peptides. Curr
Opin Lipidol, 17: 440-444, 2006.
Navab M, Ananthramaiah GM, Reddy S,
Van Lenten B, Ansell B, Hama S, Hough G, Bachini E, Grijalva V,
Wagner A, Shaposhnik Z, Fogelman A. The double jeopardy of HDL. Ann
Med, 37:173-178, 2005.
Navab M, Anantharamaiah GM, Reddy ST,
Van Lenten BJ, Wagner AC, Hama S, Hough G, Bachini E, Garber DW,
MishraVK, Palgunachari MN, and Fogelman AM. An Oral ApoJ Peptide
Renders HDL Antiinflammatory in Mice and Monkeys and Dramatically
Reduces Atherosclerosis in Apolipoprotein E–Null Mice. Arterioscler
Thromb Vasc Biol 25: 1932-1937, 2005
Van Lenten BJ, Wagner AC, Navab M,
Anantharamaiah G.M, Hui E K-W, Nayak DP, and Fogelman AM. D-4F, an
ApoA-I Mimetic Peptide, Inhibits the Inflammatory Response Induced
by Influenza A Infection of Human Type II Pneumocytes. Circulation
110: 3252-3258, 2004.
Navab M, Anantharamaiah GM, Reddy ST,
Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama SY, Hough
GP, Kamranpour N, Berliner JA, Lusis AJ, and Fogelman AM. The
oxidation hypothesis of atherogenesis: The role of oxidized
phospholipids and HDL. J Lipid Res 45: 993-1007, 2004. Navab M,
Anantharamaiah GM, Reddy ST, Van Lenten BJ, Hough G, Wagner A,
Nakamura K, Garber DW, Datta G, Segrest JP, Hama S, and Fogelman AM.
Human apolipoprotein AI and A-I mimetic peptides: potential for
atherosclerosis reversal. Curr Opin Lipidol, 15:645-649, 2004. |
